ストックスクリーナーアプリを入手
5.295
4.61%
-0.255
前日終値:
$5.55
開ける：
$5.6
24時間の取引高:
156.65K
Relative Volume:
0.37
時価総額：
$325.69M
収益：
-
当期純損益:
$-130.41M
株価収益率:
-2.3638
EPS:
-2.24
ネットキャッシュフロー:
$-67.76M
1週間 パフォーマンス:
-6.47%
1か月 パフォーマンス:
+15.09%
6か月 パフォーマンス:
-11.62%
1年 パフォーマンス:
+15.84%
1日の値動き範囲:
$5.22
$5.60
1週間の範囲:
$5.22
$5.985
52週間の値動き範囲:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
名前
Monte Rosa Therapeutics Inc
セクター
電話
617-949-2643
住所
321 HARRISON AVENUE, BOSTON
GLUE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
5.295 | 348.76M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.40 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.91 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.69 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.85 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.19 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 開始されました | UBS | Buy |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
すべてを表示
Monte Rosa Therapeutics Inc (GLUE) 最新ニュース
Can Monte Rosa Therapeutics Inc. Regain Lost Ground This QuarterLow Risk High Return Opportunities Identified - metal.it
Will Monte Rosa Therapeutics Inc. bounce back from current supportHigh Win Rate Strategy with Stop Protection - Newser
Sector ETF performance correlation with Monte Rosa Therapeutics Inc.Technical Screener for High Growth Stocks - Newser
Real time scanner hits for Monte Rosa Therapeutics Inc. explainedPredictive Screener for Daily Trade Watch - Newser
What makes Monte Rosa Therapeutics Inc. stock price move sharplyFree Stock Target Finder That Work - jammulinksnews.com
Should you hold or exit Monte Rosa Therapeutics Inc. nowMonthly Long-Term Market Recap and Summary - Newser
Sector ETF performance correlation with Monte Rosa Therapeutics Inc. Daily Entry Opportunity Forecasting Tool - Newser
Monte Rosa Therapeutics Inc. Enters Reversal Setup in Weekly ChartsReal-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Real time scanner hits for Monte Rosa Therapeutics Inc. explained Chart Pattern Recognition for Profit Timing - Newser
What institutional investors are buying Monte Rosa Therapeutics Inc. stockConsistent wealth multiplication - jammulinksnews.com
How does Monte Rosa Therapeutics Inc. generate profit in a changing economyMaximize gains with strategic stock entries - jammulinksnews.com
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention Free Accurate Buy Point for Momentum Stocks - Newser
What are the technical indicators suggesting about Monte Rosa Therapeutics Inc.Consistent high-yield stocks - jammulinksnews.com
What are the latest earnings results for Monte Rosa Therapeutics Inc.High-return market picks - jammulinksnews.com
How strong is Monte Rosa Therapeutics Inc. company’s balance sheetRemarkably fast returns - jammulinksnews.com
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attentionFree Financial Group - Newser
How Monte Rosa Therapeutics Inc. stock performs during market volatilityFree Access to Community - Newser
What analysts say about Monte Rosa Therapeutics Inc. stockOverwhelming profit margins - Autocar Professional
What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire
Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader By Investing.com - Investing.com South Africa
First-Ever NEK7 Degrader Enters Clinical Trials: Monte Rosa's Novel Approach Targets Multiple Inflammatory Diseases - Stock Titan
Monte Rosa (GLUE) Soars 13.58% in Three Days, Hits 2025 High - AInvest
Monte Rosa Therapeutics Inc (GLUE) 財務データ
収益
当期純利益
現金流量
EPS
8.67%
2.50%
大文字化:
|
ボリューム (24 時間):